Moderna to begin final phase of its COVID-19 vaccine in July
The modern biotech company announced this Thursday that the third and final phase of its vaccine against COVID-19 would begin in July, in which some 30,000 people will participate and with which it hopes to avoid symptomatic cases of the virus, prevent the mass outbreak of the disease and avoid overflow of patients in hospitals.
In a statement, Moderna, based in Cambridge, Massachusetts, stated that they could manufacture between 500 million and 1 billion doses a year starting in 2021 after reaching a collaboration agreement with the Swiss pharmaceutical company Lonza at the same time that they have guaranteed distribution of the doses necessary to complete the study.
The biotech company completed phase two of the study last month with 300 adults who had received at least one injection and is now preparing, from the United States Food and Drug Administration (FDA) and the National Institute of Allergy and Diseases Infectious (NIAID), to launch phase three next month.
"Based on the results of the phase 1 study, the 100 microgram (μg) dose level was chosen as the optimal dose level to maximize the immune response while minimizing adverse reactions," the biotech noted in the note.
Moderna chief medical officer Tal Zaks said the company was committed to advancing the clinical development of its vaccine "as quickly and safely as possible" to demonstrate the vaccine's ability to reduce the risks of COVID-19. .
According to Moderna, all participants will be monitored for at least 12 months.
After the announcement, the biotech company experienced a significant rise in the stock market. So far this year, the company has appreciated by more than 220% on Wall Street.
The biotech company completed phase two of the study last month with 300 adults who had received at least one injection and is now preparing, from the United States Food and Drug Administration (FDA) and the National Institute of Allergy and Diseases Infectious (NIAID), to launch phase three next month.
"Based on the results of the phase 1 study, the 100 microgram (μg) dose level was chosen as the optimal dose level to maximize the immune response while minimizing adverse reactions," the biotech noted in the note.
Moderna chief medical officer Tal Zaks said the company was committed to advancing the clinical development of its vaccine "as quickly and safely as possible" to demonstrate the vaccine's ability to reduce the risks of COVID-19. .
According to Moderna, all participants will be monitored for at least 12 months.
After the announcement, the biotech company experienced a significant rise in the stock market. So far this year, the company has appreciated by more than 220% on Wall Street.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.